TORONTO, Aug. 23, 2007 (PRIME NEWSWIRE) -- Cannasat Therapeutics Inc. (``Cannasat’’) (CDNX:CTH.V - News) announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310. Cannasat received a ``No Objection Letter’’ from Health Canada to conduct this clinical study for its first cannabinoid-based product that is designed to help manage neuropathic pain and other disorders.
